The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

Kate C. Tatham, Manu Shankar-Hari*, Yaseen M. Arabi

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

6 Citations (Scopus)
Original languageEnglish
Pages (from-to)1315-1318
Number of pages4
JournalIntensive Care Medicine
Issue number11
Publication statusPublished - 1 Oct 2021

Cite this